Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Jerome J Graber

Showing results (1-10 of 48) with videos related to

Pageof 5
Sort By:
Neuro-Oncology Practice|February 7, 2025
Should we be testing for germline and "actionable" mutations in all glioma patients?Jerome J Graber
Continuum (Minneapolis, Minn.)|December 12, 2023
Paraneoplastic Neurologic SyndromesJerome J Graber
Neurology|April 29, 2009
Teaching NeuroImages: "Penguin" or "hummingbird" sign and midbrain atrophy in progressive supranuclear palsyJerome J Graber, Robert Staudinger
Neurology|July 22, 2020
T2-FLAIR mismatch in isocitrate dehydrogenase mutant astrocytomas: Variability and evolutionPatrick Throckmorton, Jerome J Graber
Current Treatment Options in Oncology|January 25, 2018
Leptomeningeal MetastasesJerome J Graber, Santosh Kesari
Annals of Palliative Medicine|January 21, 2021
Palliative care in neuro-oncologyJerome J Graber, Hany Soliman
Current Opinion in Neurology|October 5, 2011
Primary central nervous system lymphoma: is there still a role for radiotherapy?Jerome J Graber, Antonio Omuro
CNS Drugs|June 9, 2011
Pharmacotherapy for primary CNS lymphoma: progress beyond methotrexate?Jerome J Graber, Antonio Omuro
Annals of Palliative Medicine|August 14, 2020
Overview of prognostic factors in adult gliomasAkanksha Sharma, Jerome J Graber
Journal of the Neurological Sciences|April 6, 2011
Biomarkers of disease activity in multiple sclerosisJerome J Graber, Suhayl Dhib-Jalbut
Pageof 5

Showing results (1-10 of 48) with videos related to

Sort By:
Pageof 5
Neuro-Oncology Practice|February 7, 2025
Should we be testing for germline and "actionable" mutations in all glioma patients?Jerome J Graber
Continuum (Minneapolis, Minn.)|December 12, 2023
Paraneoplastic Neurologic SyndromesJerome J Graber
Neurology|April 29, 2009
Teaching NeuroImages: "Penguin" or "hummingbird" sign and midbrain atrophy in progressive supranuclear palsyJerome J Graber, Robert Staudinger
Neurology|July 22, 2020
T2-FLAIR mismatch in isocitrate dehydrogenase mutant astrocytomas: Variability and evolutionPatrick Throckmorton, Jerome J Graber
Current Treatment Options in Oncology|January 25, 2018
Leptomeningeal MetastasesJerome J Graber, Santosh Kesari
Annals of Palliative Medicine|January 21, 2021
Palliative care in neuro-oncologyJerome J Graber, Hany Soliman
Current Opinion in Neurology|October 5, 2011
Primary central nervous system lymphoma: is there still a role for radiotherapy?Jerome J Graber, Antonio Omuro
CNS Drugs|June 9, 2011
Pharmacotherapy for primary CNS lymphoma: progress beyond methotrexate?Jerome J Graber, Antonio Omuro
Annals of Palliative Medicine|August 14, 2020
Overview of prognostic factors in adult gliomasAkanksha Sharma, Jerome J Graber
Journal of the Neurological Sciences|April 6, 2011
Biomarkers of disease activity in multiple sclerosisJerome J Graber, Suhayl Dhib-Jalbut
Pageof 5